| 1. |
- Andersson, Gerhard, et al.
(författare)
-
6 Internet-supported versus face-to-face cognitive behavior therapy for depression
- 2016
-
Ingår i: Expert Review of Neurotherapeutics. - : TAYLOR & FRANCIS LTD. - 1473-7175 .- 1744-8360. ; 16:1, s. 55-60
-
Forskningsöversikt (refereegranskat)abstract
- Major depression and depressive symptoms are highly prevalent and there is a need for different forms of psychological treatments that can be delivered from a distance at a low cost. In the present review the authors contrast face-to-face and Internet-delivered cognitive behavior therapy (ICBT) for depression. A total of five studies are reviewed in which guided ICBT was directly compared against face-to-face CBT. Meta-analytic summary statistics were calculated for the five studies involving a total of 429 participants. The average effect size difference was Hedges g=0.12 (95% CI: -0.06-0.30) in the direction of favoring guided ICBT. The small difference in effect has no implication for clinical practice. The overall empirical status of clinician-guided ICBT for depression is commented on and future challenges are highlighted. Among these are developing treatments for patients with more severe and long-standing depression and for children, adolescents and the elderly. Also, there is a need to investigate mechanisms of change.
|
|
| 2. |
- Andersson, Gerhard
(författare)
-
Internet-based cognitive-behavioral self help for depression
- 2006
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 6:11, s. 1637-1642
-
Tidskriftsartikel (refereegranskat)abstract
- Depression is a common condition that can be treated in many different ways. Accumulating evidence suggests that self help, based on cognitive-behavioral principles, is an evidence-based treatment for mild-to-moderate depression. Self help commonly requires some form of guidance, but can still be cost effective and the results are often similar to what can be observed in face-to-face therapy. Recently, the possibility of administering cognitive-behavioral treatment via the internet has been explored. There are several advantages to using the internet, the main one being that it bridges distances and is readily available for an increasing number of people in the world. While few controlled studies have examined the effects of internet-delivered self help for depression, the results are promising for applications that involve brief therapist input. Future possible applications of internet-based self help are discussed. © 2006 Future Drugs Ltd.
|
|
| 3. |
- Andersson, Gerhard, et al.
(författare)
-
Long-term effects of internet-supported cognitive behaviour therapy
- 2018
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 18:1, s. 21-28
-
Forskningsöversikt (refereegranskat)abstract
- Introduction: Internet-supported and therapist-guided cognitive behaviour therapy (ICBT) is effective for a range of problems in the short run, but less is known about the long-term effects with follow-ups of two years or longer.Areas covered: This paper reviews studies in which the long-term effects of guided ICBT were investigated. Following literature searches in PubMed and other sources meta-analytic statistics were calculated for 14 studies involving a total of 902 participants, and an average follow-up period of three years. Studies were from Sweden (n = 11) or the Netherlands (n = 3). Long-term outcome studies were found for panic disorder, social anxiety disorder, generalized anxiety disorder, depression, mixed anxiety and depression, obsessive-compulsive disorder, pathological gambling, stress and chronic fatigue. The duration of the treatments was usually short (8–15 weeks). The pre-to follow-up effect size was Hedge’s g = 1.52, but with a significant heterogeneity. The average symptom improvement across studies was 50%. Treatment seeking in the follow-up period was not documented and few studies mentioned negative effects.Expert commentary: While effects may be overestimated, it is likely that therapist-supported ICBT can have enduring effects. Long-term follow-up data should be collected for more conditions and new technologies like smartphone-delivered treatments.
|
|
| 4. |
- Andersson, Gerhard
(författare)
-
The latest developments with internet-based psychological treatments for depression
- 2024
-
Ingår i: Expert Review of Neurotherapeutics. - : TAYLOR & FRANCIS LTD. - 1473-7175 .- 1744-8360. ; 24:2, s. 171-176
-
Forskningsöversikt (refereegranskat)abstract
- IntroductionInternet-based psychological treatments for depression have been around for more than 20 years. There has been a continuous line of research with new research questions being asked and studies conducted.Areas coveredIn this paper, the author reviews studies with a focus on papers published from 2020 and onwards based on a Medline and Scopus search. Internet-based cognitive behavior therapy (ICBT) programs have been developed and tested for adolescents, older adults, immigrant groups and to handle a societal crisis (e.g. COVID-19). ICBT works in regular clinical settings and long-term effects can be obtained. Studies on different treatment orientations and approaches such as acceptance commitment therapy, unified protocol, and tailored treatments have been conducted. Effects on quality-of-life measures, knowledge acquisition and ecological momentary assessment as a research tool have been reported. Factorial design trials and individual patient data meta-analysis are increasingly used in association with internet intervention research. Finally, prediction studies and recent advances in artificial intelligence are mentioned.Expert opinionInternet-delivered treatments are effective, in particular if therapist guidance is provided. More target groups have been covered but there are many remaining challenges including how new tools like artificial intelligence will be used when treating depression.
|
|
| 5. |
- Archer, Trevor, 1949
(författare)
-
Neurodegeneration in schizophrenia.
- 2010
-
Ingår i: Expert review of neurotherapeutics. - : Informa UK Limited. - 1744-8360 .- 1473-7175. ; 10:7, s. 1131-41
-
Tidskriftsartikel (refereegranskat)abstract
- The neurodegenerative aspect of schizophrenia presupposes gene-environmental interactions involving chromosomal abnormalities and obstetric/perinatal complications that culminate in predispositions that impart a particular vulnerability for drastic and unpredictable precipitating factors, such as stress or chemical agents. The notion of a neurodevelopmental progression to the disease state implies that early developmental insults, with neurodegenerative proclivities, evolve into structural brain abnormalities involving specific regional circuits and neurohumoral agents. This neurophysiological orchestration is expressed in the dysfunctionality observed in premorbid signs and symptoms arising in the eventual diagnosis, as well as the neurobehavioral deficits reported from animal models of the disorder. The relative contributions of perinatal insults, neonatal ventral hippocampus lesion, prenatal methylazoxymethanol acetate and early traumatic experience, as well as epigenetic contributions, are discussed from a neurodegenerative view of the essential neuropathology. It is implied that these considerations of factors that exert disruptive influences upon brain development, or normal aging, operationalize the central hub of developmental neuropathology around which the disease process may gain momentum. Nonetheless, the status of neurodegeneration in schizophrenia is somewhat tenuous and it is possible that brain imaging studies on animal models of the disorder, which may describe progressive alterations to cortical, limbic and ventricular structures similar to those of schizophrenic patients, are necessary to resolve the issue.
|
|
| 6. |
|
|
| 7. |
- Carlborg, Andreas, et al.
(författare)
-
Suicide in schizophrenia
- 2010
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 10:7, s. 1153-64
-
Forskningsöversikt (refereegranskat)abstract
- Schizophrenia is a disorder with an estimated suicide risk of 4-5%. Many factors are involved in the suicidal process, some of which are different from those in the general population. Clinical risk factors include attempted suicide, depression, male gender, substance abuse and hopelessness. Biosocial factors, such as a high intelligence quotient and high level of premorbid function, have also been associated with an increased risk of suicide in patients with schizophrenia. Suicide risk is especially high during the first year after diagnosis. Many of the suicides occur during hospital admission or soon after discharge. Management of suicide risk includes both medical treatment and psychosocial interventions. Still, risk factors are crude; efforts to predict individual suicides have not proved useful and more research is needed.
|
|
| 8. |
- Cortese, Samuele, et al.
(författare)
-
The management of sleep disturbances in children with attention-deficit/hyperactivity disorder (ADHD) : an update of the literature
- 2024
-
Ingår i: Expert Review of Neurotherapeutics. - : Expert Reviews Ltd.. - 1473-7175 .- 1744-8360. ; 24:6, s. 585-596
-
Forskningsöversikt (refereegranskat)abstract
- INTRODUCTION: Sleep disorders represent an important comorbidity in individuals with ADHD. While the links between ADHD and sleep disturbances have been extensively investigated, research on the management of sleep disorders in individuals with ADHD is relatively limited, albeit expanding.AREAS COVERED: The authors searched PubMed, Medline, PsycInfo, Embase+Embase Classic, Web of Sciences databases, and clinicaltrials.gov up to 4 January 2024, for randomized controlled trials (RCTs) of any intervention for sleep disorders associated with ADHD. They retained 16 RCTs (eight on pharmacological and eight on non-pharmacological interventions), supporting behavioral intervention and melatonin, and nine ongoing RCTs registered on clinicaltrials.gov. EXPERT OPINION: The pool of RCTs testing interventions for sleep disorders in individuals with ADHD is expanding. However, to inform clinical guidelines, there is a need for additional research in several areas, including 1) RCTs based on a precise phenotyping of sleep disorders; 2) pragmatic RCTs recruiting neurodevelopmental populations representative of those seen in clinical services; 3) trials testing alternative interventions (e.g. suvorexant or light therapy) or ways to deliver them (e.g. online); 4) sequential and longer-term RCTs; 5) studies testing the impact of sleep interventions on outcomes other than sleep; 6) and implementation of advanced evidence synthesis and precision medicine approaches.
|
|
| 9. |
- Cyrous, Alma, et al.
(författare)
-
New approaches to bedside monitoring in stroke
- 2012
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 12:8, s. 915-928
-
Forskningsöversikt (refereegranskat)abstract
- Stroke is a common, potentially devastating disease with potential high morbidity and mortality. Recognition at the onset of acute ischemic stroke is pivotal to changing outcomes such as intravenous thrombolysis. Stroke monitoring is a burgeoning field with various methods described and newer devices that aid in detecting acute or worsening ischemia that can lead to improved bedside and intensive care unit management. This article describes various methods of bedside stroke monitoring including newer techniques of intracranial pressure monitoring using the pressure reactivity index and compensatory reserve index to detect changes in autoregulatory states, noninvasive intracranial pressure monitoring, quantitative EEG with alpha-delta ratio, transcranial Doppler, methods of arteriovenous brain oxygen monitoring such as jugular venous oxygen and near-infrared spectroscopy, invasive brain oxygen probes such as Licox™ (brain tissue O2), cerebral blood flow probe (CBF Hemedex™) and cerebral microdialysis. © 2012 Expert Reviews Ltd.
|
|
| 10. |
- Dobrosavljevic, Maja, 1986-, et al.
(författare)
-
The diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD) in older adults
- 2023
-
Ingår i: Expert Review of Neurotherapeutics. - : Expert Reviews Ltd.. - 1473-7175 .- 1744-8360. ; 23:10, s. 883-893
-
Forskningsöversikt (refereegranskat)abstract
- INTRODUCTION: There is a striking knowledge gap on ADHD in older adults, and the diagnosis as well as treatment for ADHD in this age group.AREAS COVERED: The authors first review the literature on the prevalence, functional impairment, and health comorbidities of ADHD across the lifespan. Next, they address the diagnostic criteria for ADHD in adults according to the DSM/ICD, available screening/diagnostic tools, differential diagnosis, and the validity of diagnostic criteria for ADHD in older adults. Finally, the authors focus on empirical evidence on the prevalence rates, medication response, and safety of pharmacological treatment of ADHD in older adults, and national and international clinical guidelines on the treatment of ADHD in this age group. EXPERT OPINION: It is expected that future editions of the DSM and ICD will provide specifiers to the standard ADHD criteria, to better inform the diagnosis of ADHD in older adults. It is also expected that the increasing number of epidemiological studies will provide rigorous estimates on the prevalence, incidence, and burden of ADHD in older adults. One may expect an increasing number of RCTs assessing the efficacy/effectiveness and tolerability/safety of pharmacological as well as non-pharmacological interventions which will inform future guidelines on ADHD in older adults.
|
|
| 11. |
- Foltynie, Thomas, et al.
(författare)
-
Surgical management of Parkinson's disease
- 2010
-
Ingår i: Expert review of neurotherapeutics. - : Informa UK Limited. - 1744-8360 .- 1473-7175. ; 10:6, s. 903-914
-
Tidskriftsartikel (refereegranskat)abstract
- There has been a renaissance in the surgical treatment of Parkinson's disease (PD) over the last 15-20 years as a result of the long-term complications of L-DOPA use. The current cornerstone of surgical treatment for PD is high-frequency deep-brain stimulation (DBS) of the subthalamic nucleus (STN) using implantable electrodes and an implantable pulse generator/battery. Among well-selected patients, that is, patients with idiopathic PD, L-DOPA-responsive symptoms and no significant psychiatric comorbidities or cognitive decline, STN DBS can provide improvements in motor symptoms and quality of life, with low risks of adverse effects. In this article, we briefly describe the evolution of surgical treatments for PD, and the rationale for current DBS procedures. We also provide details of our practice, including patient selection, surgical technique and postoperative stimulation programming and medication adjustment. Current and possible future alternatives to DBS of the STN are also discussed.
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
- Hampel, Harald, et al.
(författare)
-
Advances in the therapy of Alzheimer's disease : targeting amyloid beta and tau and perspectives for the future
- 2015
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 15:1, s. 83-105
-
Forskningsöversikt (refereegranskat)abstract
- Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis- and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre- and asymptomatic at-risk stages of AD.
|
|
| 16. |
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
- Johansson, Robert, et al.
(författare)
-
Internet-based psychological treatments for depression
- 2012
-
Ingår i: Expert Review of Neurotherapeutics. - : Expert Reviews Ltd. - 1473-7175 .- 1744-8360. ; 12:7, s. 861-870
-
Forskningsöversikt (refereegranskat)abstract
- Major depression is highly prevalent, and is associated with high societal costs and individual suffering. Evidence-based psychological treatments obtain good results, but access to these treatments is limited. One way to solve this problem is to provide internet-based psychological treatments, for example, with therapist support via email. During the last decade, internet-delivered cognitive-behavioral therapy (ICBT) has been tested in a series of controlled trials. However, the ICBT interventions are delivered with different levels of contact with a clinician, ranging from nonexisting to a thorough pretreatment assessment in addition to continuous support during treatment. In this review, the authors have found an evidence for a strong correlation between the degree of support and outcome. The authors have also reviewed how treatment content in ICBT varies among treatments, and how various therapist factors may influence outcome. Future possible applications of ICBT for depression and future research needs are also discussed.
|
|
| 20. |
- Kobelt, Gisela
(författare)
-
Health economic evaluation: why? When? How?
- 2013
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1744-8360 .- 1473-7175. ; 13:12, s. 33-37
-
Forskningsöversikt (refereegranskat)abstract
- Advances in research and better understanding of the pathophysiology of diseases have resulted in an increase in the number of available health interventions that compete for finite public resources. Explicit choices must therefore be made about funding.
|
|
| 21. |
- Koehler, Jürgen, et al.
(författare)
-
Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.
- 2013
-
Ingår i: Expert review of neurotherapeutics. - : Informa UK Limited. - 1744-8360 .- 1473-7175. ; 13:12 Suppl, s. 61-6
-
Forskningsöversikt (refereegranskat)abstract
- Spasticity is one of the main symptoms associated with multiple sclerosis (MS). Epidemiological studies indicate that approximately two-thirds of MS patients experience spasticity and, in a relevant proportion of this group, spasticity is moderate to severe. Yet, spasticity remains largely undertreated. The most commonly used oral antispasticity agents (e.g., baclofen, tizanidine, gabapentin) generally do not reduce spasticity adequately at dosages that are well tolerated by patients. This review of MS spasticity cases from around Europe presents current knowledge of considerations for administration of a new agent (tetrahydrocannabinol/cannabidiol-based nabiximols [Sativex®] oromucosal spray) for management of MS spasticity, with the aim of ensuring appropriate and optimal use for best outcomes. Assessment of the European clinical experience is intended to provide a better understanding of the prescribing regulations for MS spasticity treatments, facilitate identification of suitable candidate patients for Sativex and increase awareness of alternative management approaches for MS-related spasticity.
|
|
| 22. |
- Landtblom, Anne-Marie, 1953-
(författare)
-
Treatment of erectile dysfunction in multiple sclerosis
- 2006
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 6:6, s. 931-935
-
Tidskriftsartikel (refereegranskat)abstract
- Erectile dysfunction in men with multiple sclerosis (MS) is a very common symptom that often leads to a reduced quality of life. It is related to neurological dysfunction, psychological factors, side effects of medication or generalized MS symptoms, such as fatigue or micturition problems, usually in combination. The question of sexual dysfunction should always be broached during routine follow-up, regardless of age and social status. The possibility that erection problems can be a side-effect of drugs commonly used in MS must also be remembered. There are several effective pharmacological treatments, such as phosphodiesterase inhibitors and prostaglandin E1 (alprostadil). The contraindications and side effects should be familiar to the MS doctor. Dose titration in the initial stages is recommended to avoid priapism. In the future, combinations of impotence drugs may be tested. © 2006 Future Drugs Ltd.
|
|
| 23. |
- Olsson, Bob, 1969, et al.
(författare)
-
The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials
- 2017
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 17:8, s. 767-775
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: All recent phase 3 trials of potentially disease-modifying therapies for Alzheimer's disease (AD) have so far failed. Potential reasons include enrolling subjects whose disease is too advanced or who do not have AD pathology, or simply incorrect drug targets. The goal of disease-modifying AD trials is to halt the progress of neuronal damage and death and this can be assessed in vivo using cerebrospinal fluid (CSF) biomarkers.Areas covered: The authors conducted a literature search of the use of CSF biomarkers in disease-modifying AD clinical trials using PubMed. The authors show that CSF biomarkers have only sparsely been used as outcome measures, and where they have, only in small subsets of patients. No clinical trials have yet showed any substantial effects on CSF biomarkers of neurodegeneration.Expert commentary: In future trials, the authors advocate that CSF biomarkers be used more extensively to optimize the chance of detecting positive drug effects. This includes the identification of potential AD patients - already in the early prodromal stage - for inclusion, for stratification, as readout i.e. proximity markers for changes in axonal/neurodegeneration between treatment and placebo groups - this also enables proof of principle verification in the discovery/dose finding phase, and for monitoring of side effects.
|
|
| 24. |
- Pergolizzi, Joseph V., et al.
(författare)
-
Identifying risk factors for chronic postsurgical pain and preventive measures : a comprehensive update
- 2023
-
Ingår i: Expert Review of Neurotherapeutics. - : Expert Reviews Ltd.. - 1473-7175 .- 1744-8360. ; 23:12, s. 1297-1310
-
Forskningsöversikt (refereegranskat)abstract
- INTRODUCTION: Chronic postsurgical pain (CPSP) is a prevalent condition that can diminish health-related quality of life, cause functional deficits, and lead to patient distress. Rates of CPSP are higher for certain types of surgeries than others (thoracic, breast, or lower extremity amputations) but can occur after even uncomplicated minimally invasive procedures. CPSP has multiple mechanisms, but always starts as acute postsurgical pain, which involves inflammatory processes and may encompass direct or indirect neural injury. Risk factors for CPSP are largely known but many, such as female sex, younger age, or type of surgery, are not modifiable. The best strategy against CPSP is to quickly and effectively treat acute postoperative pain using a multimodal analgesic regimen that is safe, effective, and spares opioids.AREAS COVERED: This is a narrative review of the literature.EXPERT OPINION: Every surgical patient is at some risk for CPSP. Control of acute postoperative pain appears to be the most effective approach, but principles of good opioid stewardship should apply. The role of regional anesthetics as analgesics is gaining interest and may be appropriate for certain patients. Finally, patients should be better informed about their relative risk for CPSP.
|
|
| 25. |
- Pergolizzi, Joseph V. Jr., et al.
(författare)
-
Developments in combined analgesic regimens for improved safety in postoperative pain management
- 2020
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 20:9, s. 981-990
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Fixed-dose combination analgesic regimens may be similarly effective to opioid monotherapy but with potentially less risk. A number of individualized combination regimens can be created, including nonopioid agents such as acetaminophen and nonsteroidal anti-inflammatory drugs, opioids, and adjunctive agents such as gabapentin, pregabalin, and muscle relaxants.Areas covered: When such combinations have a synergistic effect, analgesic benefits may be enhanced. Many combination analgesic regimens are opioid sparing, which sometimes but not always results in reduced opioid-associated side effects. Safety concerns for all analgesics must be considered but postoperative analgesia is typically administered for a brief period (days), reducing risks that may occur with prolonged exposure.Expert opinion: Judiciously considered combination analgesic regimens can be effective postoperative analgesics that reduce opioid consumption without compromising pain control, which are important factors for patient recovery and satisfaction. The specific combinations used must be based on the patient, the type and duration of the surgical procedure, and complementary mechanisms of action of the agents used. In opioid-sparing combination analgesic regimens, the short-term use of small doses of opioids in this setting may be helpful for appropriate patients.
|
|
| 26. |
- Qiu, Chengxuan
(författare)
-
Epidemiological findings of vascular risk factors in Alzheimer’s disease : implications for therapeutic and preventive intervention
- 2011
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 11:11, s. 1593-1607
-
Tidskriftsartikel (refereegranskat)abstract
- Alzheimer’s disease (AD) is a multifactorial disorder, in which the detrimental effects of vascular risk factors and related disorders (e.g., smoking, obesity, hypertension, diabetes, dyslipidemia and inflammation) have been frequently suggested in numerous observational studies of the general population. In recent years, systematic reviews and meta-analyses of population-based prospective studies have concluded from the life-course perspective, an age-dependent association with the risk of AD for several vascular factors, such as high blood pressure, obesity and high total cholesterol, such that possessing these factors in midlife is associated with an increased risk of late-life AD, whereas having a low level in late life or a decline after middle age in these factors may anticipate clinical onset of AD. The biological plausibility for these vascular factors and related disorders being involved in the pathogenesis and clinical manifestation of AD is also supported by population-based neuroimaging and neuropathological studies. However, randomized placebo-controlled trials that target those major cardiovascular risk factors (e.g., antihypertensive, hormone replacement and anti-inflammatory therapies) have generally failed to prove to be efficacious preventive or therapeutic approaches for AD. The multifactorial nature of AD and the age-dependent relationship between vascular risk factors and the risk of AD should be taken into consideration in the future when designing preventive or therapeutic intervention against the dementing disorder.
|
|
| 27. |
|
|
| 28. |
- Salzer, Jonatan, et al.
(författare)
-
Vitamin D and multiple sclerosis : where do we go from here?
- 2014
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa. - 1473-7175 .- 1744-8360. ; 14:1, s. 9-18
-
Forskningsöversikt (refereegranskat)abstract
- This article briefly introduces the basics of multiple sclerosis' (MS) clinical hallmarks and pathophysiology. Vitamin D is presented, including its metabolism and effects on the immune system. The epidemiological observations linking vitamin D to MS range from a half century old findings of latitude gradients and migrational risk patterns to modern, nested, case-control biobank studies. These observations show an association without doubt although causation has yet to be proven. Vitamin D as a treatment for MS is an emerging concept and both current and anticipated data will be covered. Lastly, we discuss future challenges, ideas on how to move from association to causation, and the prospect of primary prevention of this disabling disease.
|
|
| 29. |
|
|
| 30. |
|
|
| 31. |
|
|
| 32. |
- Sharma, Hari Shanker
(författare)
-
5th Annual Global College of Neuroprotection and Neuroregeneration
- 2008
-
Ingår i: Expert review of neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 8:6, s. 881-7
-
Tidskriftsartikel (refereegranskat)abstract
- The 5th Global College of Neuroprotection and Neuroregeneration (GCNN) was held in the historic charming capital city of Bucharest, Romania in JW Marriott Grand Hotel on 3-6 March, 2008. The meeting was a unique blend of basic researchers and clinicians across the Globe presenting their recent findings in neuroprotection and neuroregeneration in a beautiful exotic ambience. More than 300 students and researchers attended the congress and participated in deliberations. Over 60 representatives from various pharmaceutical industries from all over the world supported this event. This meeting was held for the first time as a joint venture with GCNN and the Society for study on Neuroproetction and Neuroplasticity (SSNN), and was a grand success both scientifically and socially. Thus, these joint meetings of the two societies (GCNN and SSNN) will continue in future in different European cities for the coming 5 years.
|
|
| 33. |
- Sharma, Hari Shanker, et al.
(författare)
-
6th Global College of Neuroprotection and Neuroregeneration, annual meeting
- 2009
-
Ingår i: Expert review of neurotherapeutics. - : Informa UK Limited. - 1744-8360 .- 1473-7175. ; 9:7, s. 941-947
-
Tidskriftsartikel (refereegranskat)abstract
- The 6th Global College of Neuroprotection and Neuroregeneration (GCNN) and 5th Society for Study on Neuroplasticity and Neuroregeneration (SSNN) conference was held jointly in the Hilton Hotel, Vienna, Austria, 1-4 March 2009. This was the second annual joint conference of the two societies and it was highly successful from a scientific point of view, as it saw a gathering of the top basic and clinical scientists whose research is currently at the cutting edge of neuroscience. This conference saw 86 invited lectures from carefully selected leading scientists from around the world, along with 56 posters of young scientists researching of a focal theme. Over the 3 days, in 32 sessions, new developments in neuroprotection and new ways to enhance neuroregeneration were discussed intensively among more than 600 delegates. In addition, approximately 40 representatives of drug companies, five representatives from scientific publishers and 14 representatives from scientific instruments and supplies-related industries also actively participated in this huge neuroscience event. The GCNN and SSNN conference achieved a new milestone in scientific success in Vienna and established an excellent new working collaboration among the participants in a pleasant, enriched environment with several social gatherings.
|
|
| 34. |
- Sharma, Hari Shanker, et al.
(författare)
-
New perspectives on molecular and cellular mechanisms of neuroprotection and neuroregeneration : part I
- 2010
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 10:7, s. 1039-1043
-
Tidskriftsartikel (refereegranskat)abstract
- Recent developments in the rapidly advancing area of neuroprotection and neuroregeneration necessitated the need to gather over 50 of the world's leading experts under the umbrella of the Global College of Neuroprotection and Neuroregeneration (GCNN) in its 7th Annual Meeting in Stockholm, Sweden. In this meeting, top policy-makers, together with world leaders in pharmaceutical industries, discussed the urgent need to develop new pharmaceuticals, as well as using a combination of existing ones, to treat CNS disorders in order to improve the current status of healthcare. In addition, nanobiotechnologists proposed the use of a new formulation of drugs using nanotechnologies for enhanced drug delivery to the brain for better therapeutic efficacy of the neuroprotective agents. The deliberations in this meeting provide new perspectives on the molecular and cellular mechanisms of neuroprotection and neuroregeneration that could be utilized to improve the existing healthcare for the benefit of mankind.
|
|
| 35. |
- Sharma, Hari Shanker, et al.
(författare)
-
New perspectives on molecular and cellular mechanisms of neuroprotection and neuroregeneration : part II
- 2010
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 10:8, s. 1253-1257
-
Tidskriftsartikel (refereegranskat)abstract
- Recent developments in the rapidly advancing area of neuroprotection and neuroregeneration necessitated the need to gather over 50 of the world's leading experts under the umbrella of the Global College of Neuroprotection and Neuroregeneration in its 7th Annual Meeting in Stockholm, Sweden. In this meeting, top policy-makers, together with world leaders in pharmaceutical industries, discussed the urgent need to develop new pharmaceuticals, as well as using a combination of existing ones, to treat CNS disorders in order to improve the current status of healthcare. In addition, nanobiotechnologists proposed the use of a new formulation of drugs using nanotechnologies for enhanced drug delivery to the brain for better therapeutic efficacy of the neuroprotective agents. The deliberations in this meeting provide new perspectives on the molecular and cellular mechanisms of neuroprotection and neuroregeneration that could be utilized to improve the existing healthcare for the benefit of mankind.
|
|
| 36. |
- Sharma, Hari Shanker, et al.
(författare)
-
New strategies for CNS injury and repair using stem cells, nanomedicine, neurotrophic factors and novel neuroprotective agents
- 2011
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 11:8, s. 1121-1124
-
Tidskriftsartikel (refereegranskat)abstract
- The 8th Annual Conference of the Global College of Neuroprotection and Neuroregeneration (GCNN) was global in the true sense of the word as it was held beyond European boundaries for the first time in the beautiful ambience of the ancient and modern environment of the Hashemite Kingdom of Jordan on 27–30 April 2011. The meeting was organized together with the 4th International Association of Neurorestoratology (IANR; Beijing, China) and the 11th meeting of the American Society for Neural Therapy and Repair (ASNTR; FL, USA). The first joint meeting was extremely successful and attracted more than 600 delegates including top experts, research students and educators from industry, academia, research organizations, universities and medical representatives from across the globe. The focal theme of this meeting was ‘Exploring new strategies for neuroregenerative therapy for CNS injury and repair’. The Jordanian Association of Orthopedic Surgeons chaired by Ziad Al Zoubi served as the local host. HRH Princess Basma Bint Talal of Jordan inaugurated the congress. The salient new discoveries and recommendations for future strategies discussed during the meeting are summarized in this article.
|
|
| 37. |
- Sharma, Hari Shanker, et al.
(författare)
-
New therapeutic advances in CNS injury and repair
- 2012
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 12:8, s. 901-905
-
Tidskriftsartikel (refereegranskat)abstract
- 9th Global College of Neuroprotection & Neuroregeneration (GCNN) Annual Conference Xi'an, Shaanxi Province, China, 4-7 May 2012 The 9th Global College of Neuroprotection and Neuroregeneration annual meeting was held in cooperation with the 5th International Association of Neurorestoratology and the 4th International Spinal Cord Injury Treatment and Trial Symposium in the beautiful city of Xi'an, Shaanxi Province, China, between 4 and 7 May 2012. This trilateral conference was held in the pleasing ambience of the Sofitel Hotel Complex in Renmin Square, Xi'an. Top Chinese government dignitaries including the National Deputy Health Minister, Vice Governor of Shaanxi Province, Vice President of Xi'an Jiaotong University and Party Secretary of the Medical Association inaugurated the congress. More than 1000 delegates from across the world, including approximately 600 medical researchers from China, participated in this meeting. The theme of this meeting was 'neurorestoration and neurorepair' using stem cell treatment, antibodies and pharmacotherapy, as well as nanomedicine and neurorehabilitation. Preclinical and clinical research was presented and discussed. Use of nanomedicine to enhance neurorepair or diagnosis of neurological diseases in clinical situations was the new attraction in this trilateral meeting. More than 50 leading experts in neuroprotection and neurorestoratology presented their cutting edge research in the area. New features included the Youth Forum in which 12 young scientists presented their innovative results, and more than 30 platform presentations were included. Thus, the trilateral conference of the Global College of Neuroprotection and Neuroregeneration, the International Association of Neurorestoratology and the International Spinal Cord Injury Treatment and Trial Symposium was extremely successful from both the scientific and social perspectives.
|
|
| 38. |
- Sharma, Hari Shanker, et al.
(författare)
-
Novel therapeutic strategies using nanodrug delivery, stem cells and combination therapy for CNS trauma and neurodegenerative disorders
- 2013
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 13:10, s. 1085-1088
-
Forskningsöversikt (refereegranskat)abstract
- The 10th Global College of Neuroproetction and Neuroregeneration Annual Conference together with the International Association of Neurorestoratology VI was held in Bucharest under the auspicious of the Society for the Study of Neuroprotection and Neuroplasticity during 4-7 April 2013. The focus of these unified societies meeting was on neurorestoration, neuroprotection and neuroregeneration in various clinical neurodegenerative diseases; for example, Alzheimer's, Parkinson's, Huntington's disease, stroke and brain or spinal cord injuries. The main aim to enhance healthcare was suggested by the use of stem cells, nanodrug delivery of drugs and stem cells, use of multimodal drugs as well as a combination of different approaches. The meeting was attended by more than 500 delegates including researches, policy makers and healthcare professionals along with several representatives from drug industries from Europe and USA. It appears that future of neuroprotection could be achieved by the use of stem cells and nanodrug delivery in chronic neurological disorders.
|
|
| 39. |
- Sjostrand, C
(författare)
-
Genetic aspects of cluster headache
- 2009
-
Ingår i: Expert review of neurotherapeutics. - : Informa UK Limited. - 1744-8360 .- 1473-7175. ; 9:3, s. 359-368
-
Tidskriftsartikel (refereegranskat)
|
|
| 40. |
|
|
| 41. |
- Wang, Shuhui, et al.
(författare)
-
Advances in autoimmune myasthenia gravis management
- 2018
-
Ingår i: Expert Review of Neurotherapeutics. - : TAYLOR & FRANCIS LTD. - 1473-7175 .- 1744-8360. ; 18:7, s. 573-588
-
Forskningsöversikt (refereegranskat)abstract
- Introduction: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder with no cure and conventional treatments limited by significant adverse effects and variable benefit. In the last decade, therapeutic development has expanded based on improved understanding of autoimmunity and financial incentives for drug development in rare disease. Clinical subtypes exist based on age, gender, thymic pathology, autoantibody profile, and other poorly defined factors, such as genetics, complicate development of specific therapies.Areas covered: Clinical presentation and pathology vary considerably among patients with some having weakness limited to the ocular muscles and others having profound generalized weakness leading to respiratory insufficiency. MG is an antibody-mediated disorder dependent on autoreactive B cells which require T-cell support. Treatments focus on elimination of circulating autoantibodies or inhibition of effector mechanisms by a broad spectrum of approaches from plasmapheresis to B-cell elimination to complement inhibition.Expert commentary: Standard therapies and those under development are disease modifying and not curative. As a rare disease, clinical trials are challenged in patient recruitment. The great interest in development of treatments specific for MG is welcome, but decisions will need to be made to focus on those that offer significant benefits to patients.
|
|
| 42. |
- Zetterberg, Henrik, 1973, et al.
(författare)
-
Understanding the cause of sporadic Alzheimer's disease
- 2014
-
Ingår i: Expert Review of Neurotherapeutics. - : Informa UK Limited. - 1473-7175 .- 1744-8360. ; 14:6, s. 621-630
-
Forskningsöversikt (refereegranskat)abstract
- The increasing prevalence of Alzheimer's disease (AD) and a lack of effective prevention or disease-modifying therapies are global challenges with devastating personal, social and economic consequences. The amyloid (A) hypothesis posits that cerebral -amyloidosis is a critical early event in AD pathogenesis. However, failed clinical trials of A-centric drug candidates have called this hypothesis into question. Whereas we acknowledge that the A hypothesis is far from disproven, we here re-visit the links between A, tau and neurodegeneration. We review the genetics, epidemiology and pathology of sporadic AD and give an updated account of what is currently known about the molecular pathogenesis of the disease.
|
|
| 43. |
- Carlborg, A, et al.
(författare)
-
Suicide in schizophrenia
- 2010
-
Ingår i: Expert review of neurotherapeutics. - 1744-8360. ; 10:7, s. 1153-1164
-
Tidskriftsartikel (refereegranskat)
|
|
| 44. |
|
|
| 45. |
|
|
| 46. |
|
|
| 47. |
|
|
| 48. |
|
|
| 49. |
|
|
| 50. |
|
|
